Relief of pain · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Levamisole (150 mg per day) showed no clear difference in decrease in pain compared with placebo; GRADE not reported.
1 finding from 1 review
RR 4.29 [0.67, 27.24]
1 study
GRADE not reported
Decrease in frequency of attacks · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Levamisole (150 mg per day) showed no clear difference in decrease in frequency of attacks compared with placebo; GRADE not reported.
1 finding from 1 review
RR 4.29 [0.72, 25.39]
1 study
GRADE not reported
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Patients receiving levamisole reported more adverse effects than those receiving placebo (mild stomach upset/nausea, diarrhoea, sleeplessness, dysgeusia/dysosmia), however no adverse effects were reported as requiring…
8 studies
GRADE not reported
Effectiveness · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Decrease in duration of attacks · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Levamisole (150 mg per day) showed no clear difference in decrease in duration of attacks compared with placebo; GRADE not reported.
1 finding from 1 review
RR 4.29 [0.67, 27.24]
1 study
GRADE not reported
Decrease in number of ulcers · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Levamisole (150 mg per day) showed no clear difference in decrease in number of ulcers compared with placebo; GRADE not reported.
1 finding from 1 review
RR 7.88 [0.51, 121.96]
1 study
GRADE not reported
Adverse effects · Children (permanent teeth; baseline 8 to 10 years)
1 finding from 1 review
Caries increment, surface index D(M)FS · Children (permanent teeth; baseline 8 to 10 years)
1 finding from 1 review
Number of children with a caries increment · Children (permanent teeth; baseline 8 to 10 years)
Xylitol lozenges (4.7 g/day) showed no clear difference in number of children with a caries increment compared with no treatment; GRADE not reported.
1 finding from 1 review
Number of infants with a caries increment · Infants/young children (primary teeth; baseline about 1 to 3 years)
Xylitol sucking tablets (1 g/day) showed no clear difference in number of infants with a caries increment compared with no treatment; GRADE not reported.
1 finding from 1 review
Caries increment, surface index D(M)FS · Infants/young children (primary teeth; baseline about 1 to 3 years)
1 finding from 1 review
Adverse effects (narrative) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months)
SoF4. Adverse effects: single study narratively reported 4 participants (20%) in the bethanechol arm experienced adverse events (nausea, dizziness, blood pressure fall, cold perspiration or sporadic abdominal pain);…
1 study · 40 participants
Very low
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether cholinergics (bethanechol 15 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Frequency of adverse effects ‐ dizziness ( · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: dizziness compared with placebo (very low certainty).
1 finding from 1 review
Adverse event: tremor · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: tremor compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Abdominal pain · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: abdominal pains compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: headache · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: headache compared with placebo (very low certainty).
1 finding from 1 review